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ABSTRACT: Fe3O4@astragalus polysaccharide core-shell nanoparticles 
(Fe3O4@APS NPs) were demonstrated to be an efficient therapeutic drug for treating 
iron deficiency anemia (IDA) in vivo. The Fe3O4@APS NPs have been synthesized 
using a two steps approach involving hydrothermal synthesis and subsequent 
esterification. Transmission electron microscopy (TEM) and Fourier transform 
infrared (FTIR) spectroscopy studies show that APS are attached on the surfaces of 
the highly monodisperse Fe3O4 NPs. Dynamic light scatting (DLS) and magnetic 
characterizations reveal that the Fe3O4@APS NPs have outstanding water solubility 
and stability. Cytotoxicity assessment using Hela cells and pathological tests in mice 
demonstrate their good biocompatibility and low toxicity. The IDA treatment in rats 
shows that they have efficient therapeutic effect, which is contributed to both the iron 
element supplement from Fe3O4 and the APS-stimulated hematopoietic cell 
generation. Moreover, the Fe3O4@APS NPs are superparamagnetic and thus able to 
be used for magnetic resonance imaging (MRI). This study has demonstrated the 
potential of nanocomposites involving purified natural products from Chinese herb 
medicine for biomedical applications. 
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Iron is one of the most important trace elements in human body and is essential for 
the normal function of organisms, particularly for the metabolism and immune 
functions. 
[1]
 As reported by World Health Organization, 2 billion people have anemia, 
with nearly 1 billion suffering from iron deficiency anemia (IDA).
[2]
 Therefore, IDA 
is a common nutritional disease in modern society.
[3]
 Oral iron supplementation, such 
as ferrous salts, is common in the treatment and prevention of iron deficiency in 
human body.
[4]
 However, it usually causes side effects, such as epigastric pain, 
diarrhea and constipation.
[5]
 Therefore, it is highly desired to develop new iron 
supplements with no or few side effects.
[6]
 
Ferumoxide, known as Feridex in America and Endorem in Europe, is a colloid of 
ultra-small superparamagnetic iron oxide (USPIO) nanoparticles (NPs) coated by 
dextran.
[7]
 It is a FDA-cleared drug for the treatment of IDA in adult chronic kidney 
disease patients. 
[8]
 
[9]
 After intravenous administration, the USPIO NPs are cleared 
from blood by phagocytosis.
[10]
 The USPIO NPs are metabolized in the lysosomes 
into a soluble, nonmagnetic form of iron that becomes part of the normal iron pool 
after the intracellular uptake.
 
Among the USPIO NPs, Fe3O4 NPs have been proved to 
exhibit good superparamagnetic property below 15 nm and can be used as both an 
iron supplement and a magnetic resonance imaging (MRI) contrast agent candidate.
 
[11]
 
MRI is a powerful noninvasive diagnostic technique for visualizing the fine 
structure of the human body with high spatial resolution. To obtain accurate diagnosis, 
contrast agents are usually used to increase the MRI image quality by exerting an 
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influence on the longitudinal (T1), transverse (T2) relaxation time and T2-star (T2*), a 
relaxation parameter arising principally from local magnetic field in homogeneities 
that are increased with iron deposition.
[12]
 Due to the unique superparamagnetic 
property, Fe3O4 NPs have been widely used as ultrasensitive negative contrast agents 
for early detection of tumors due to their strong T2 and T2* shortening effect.
[13]
   
Unfortunately, the exposed Fe3O4 NPs have poor solubility and biocompatibility. 
Therefore, the surface of Fe3O4 NPs needs to be suitably engineered to acquire 
improved biocompatibility.
[14, 15]
 The most popular methods are introducing 
hydrophilic groups and modification of bioinorganic shell on the surface of Fe3O4 
NPs, which can effectively optimize the properties of Fe3O4 NPs to satisfy the 
requirements of applications, such as MRI contrast agents, 
[16]
 magnetic targeting drug, 
biomolecule separation, and hyperthermal cancer therapy.
[17] 
 For example, 
Fe3O4-based nanocomposites, such as Fe3O4@Polydopamine,
[18]
 WS2@Fe3O4,
[19]
 
Fe3O4@Au
[20]
 and C-Fe3O4 quantum dots (QDs)
[21]
, have been studied as MRI 
contrast agents and drug carriers in preclinical and clinical setting.
[22]
   
Among the modification materials of Fe3O4 NPs, polysaccharides have the 
advantages of stability, water solubility and few side effects on the organism. 
Meanwhile, some natural polysaccharides can promote the formation of 
hematopoietic cell.
[23]
 Astragalus membranaceus, a traditional Chinese herb medicine 
containing many active components, such as polysaccharides, flavonoids, saponins, 
amino acids and trace elements, has been used in China for medicine for more than 
2,000 years to improve human immunity and treat cardiovascular disorders. 
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Astragalus polysaccharide (APS) is one of the main active components of Astragalus 
membranaceus extracted from Astragalus roots, which is described in the 2005 
version of the ‘‘Chinese Pharmacopoeia”.[24] APS is comprised of uniform 
polysaccharide fraction, including rhamnose, arabinose and glucose.
[25]
 APS is stable 
and biocompatible in vivo, which makes it an ideal material for biomedical 
applications.
 
Many reports on the biological activities of APS indicate that it possesses 
potent anti-inflammatory, organ protective, anti-tumor activities and growth of red 
blood cell stimulative.
[26]
 Therefore, APS is a promising material for modifying Fe3O4 
NPs.  
To develop a potential IDA therapeutic agent combining iron supplements and 
contents of promoting the hematopoietic cell formation, we report a novel material of 
Fe3O4@APS Core-Shell NPs fabricated by a two steps approach involving 
hydrothermal synthesis
[27]
 and esterification. As shown in Figure 1a，the water 
soluble Fe3O4 NP cores were obtained in sodium citrate solution, in which sodium 
citrate replaces the oleic acid molecular on the surface of the Fe3O4 NPs. Then, The 
Fe3O4 NPs were bonded with the APS backbone, and the sodium citrate reacted with 
the hydroxyl groups of the APS chains to form the Fe3O4@APS NPs. Finally, the 
Fe3O4@APS NPs were used in mice intragastric administration for IDA treatment and 
MRI testing followed by pathological tests, after the structural stability 
characterization and cytotoxicity assessment, as depicted in Scheme 1. As expected, 
the Fe3O4@APS NPs show unique therapeutic effect for IDA treatment, which is 
much better than that of water soluble Fe3O4 NPs. This is the result of the combined 
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contribution of the hematopoietic cell generation stimulated by APS and the 
simultaneous iron element supplement from Fe3O4. Besides this, the Fe3O4@APS NPs 
are also potential MRI contrast agents in vivo, which are safe and good for health. The 
study opens a new way to design IDA medicine with USPIO NPs and natural 
polysaccharides, which can serve as a contrast agent at the same time.  
The crystal structural of the Fe3O4 NPs and Fe3O4@APS NPs were investigated by 
X-ray diffraction (XRD) (Figure S2, Supporting Information). The XRD patterns of 
both NP samples show sharp diffraction peaks of Fe3O4 (JCPDS75-0033)
[28]
 with 
Fd-3m space group, indicating good crystallinity. Figure 1b shows the transmission 
electron microscope (TEM) image of the oil-soluble Fe3O4 NPs, which are spherical 
with a uniform diameter of ~10 nm. High-resolution TEM images of the Fe3O4 NPs 
exhibit (220) and (331) crystal facets as indexed in Figure 1c. The hydrodynamic 
diameter of the water soluble Fe3O4 NPs was measured to be 11 nm by dynamic light 
scattering (DLS) (Figure 1e), which is slightly larger than that measured by TEM 
(Figure 1d).  
For the Fe3O4@APS NPs, the diameter does not show obvious increase in TEM 
image (Figure 1f), revealing clear cores of Fe3O4 NPs but insignificant evidence of the 
APS shells. This is because APS molecules are composed by C, H, O and N elements, 
which are invisible in TEM. However, the DLS results show a mean size of 29.5 nm 
for the Fe3O4@APS NPs (Figure 1g), which demonstrates the existence of the APS 
shells coated on the surface of Fe3O4 NPs. The dispersion stability of the oleic 
acid-coated Fe3O4 NPs shows good water stability and biocompatibility after the 
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ligand exchange reaction on the surface from oleic acid to sodium citrate and APS. 
The zeta potential of the water soluble Fe3O4 NPs and Fe3O4@APS NPs are -36.8 mV 
and -28.8 mV, respectively, which suggests good water dispersity of the NPs (Figure 
S3, Supporting Information).
[29]
  
Fourier transform infrared (FT-IR) absorption spectra were measured to confirm the 
presence of the APS around the Fe3O4 NPs (Figure 1h). Compared to the FT-IR 
spectrum of Fe3O4 around with oleic acid, the one of Fe3O4@APS NPs shows new 
strong absorption bands at 1383 cm
-1
 and 1633 cm
-1
, which can be attributed to the 
C-O-C and C=O stretch of APS and sodium citrate vibration of polysaccharide, 
respectively. It is evident that the oleic acid on the surface of Fe3O4 NPs was 
efficiently replaced by APS and sodium citrate. Moreover, the Fe3O4@APS NPs show 
a strong absorption band at 586 cm
-1
, attributed to Fe-O bond, while the APS 
copolymer has the stretching bands at 2921 cm
-1
 and 3424 cm
-1
, corresponding to 
hydroxyl groups, which are a further evidence of the ligand exchange on the surface 
of Fe3O4 NPs. 
To study the magnetic properties of Fe3O4@APS NPs, the magnetization curves 
have been measured, as shown in Figure 1i. All the curves exhibit no hysteresis, 
suggesting that the Fe3O4 NPs are superparamagnetic, with or without APS coating. 
The Fe3O4 NPs have a higher saturation magnetization (Ms) (about 62.2 emu/g) than 
that of the Fe3O4@APS NPs (about 36.7 emu/g), which further demonstrates the 
existence of the APS shells on the surface of Fe3O4 NPs. From the change of Ms, the 
mass percentage of the Fe3O4 NPs can be estimated to be around 60% in the 
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Fe3O4@APS NPs. With a magnet placed outside the cuvette, the Fe3O4@APS NPs in 
the water solution can rapidly accumulate near the magnet (See the inset of Figure 1i). 
When the magnet is removed, the Fe3O4@APS NPs disperse in water again, even 
after 6 months, suggesting the Fe3O4@APS NPs are superparamagnetic with good 
stability. To further investigate the magnetic behavior of the Fe3O4@APS NPs, the 
temperature dependence of their magnetization was investigated by zero-field cooling 
(ZFC) and field cooling (FC) respectively (Figure S4, Supporting Information). The 
MZFC-T curves show broad peaks with a clear maximum (Tmax) at ~226 K for the 
Fe3O4 NPs and ~167 K for the Fe3O4@APS NPs, above which temperature the 
particles are in superparamagnetic regime. Thus, both kinds of the NPs are 
superparamagnetic at 300 K.
[14]
  
Since the Fe3O4@APS NPs should be fed to the Institute of Cancer Research (ICR) 
mice and Wistar rats, it is possible that the Fe3O4@APS NPs might be degraded 
during digestion in their stomachs. Thus, we have checked the stability of the 
Fe3O4@APS NPs in imitated gastric acid by stirring in HCl solution with pH = 1.5 for 
5 h. The magnetization curve of the Fe3O4@APS NPs collected after the imitating 
digestion still shows good superparamagnetic property (as shown in Figure 1i). The 
Ms of the Fe3O4@APS NPs increases to 45.6 emu/g, which is larger than that of the 
as-prepared Fe3O4@APS NPs. This suggests that a certain amount of APS molecules 
could desorb from the NPs surfaces in the stomach due to the acid environment. 
However, comparing with the Ms of the Fe3O4 NPs, we confirmed that there is still 
sufficient amount of APS molecules attached to the Fe3O4 NPs cores. Moreover, the 
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FT-IR spectrum of the Fe3O4@APS NPs (Figure 1h) shows no significant change 
relative to that of the as-prepared Fe3O4@APS NPs, consistent with the results of the 
magnetic studies. The iron concentration in the Fe3O4@APS NPs was also 
quantitatively determined by inductively coupled plasma optical emission 
spectroscopy (ICP-OES). The weight percentage of Fe increases from 60% to 75% 
after stirring in HCl solution, which is consistent with the change of the magnetization 
curves. Accordingly, only a small amount of APS molecules were degraded by HCl 
solution. Therefore, the Fe3O4@APS NPs are stable enough and can be absorbed into 
blood as whole NPs, instead of the separate Fe3O4 NPs and APS.  
The cytotoxicity evaluation is necessary for a new biomaterial before in vivo 
applications. We assessed the biocompatibility of the Fe3O4@APS NPs with 
mammalian cells by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay using a HeLa cell line. As shown in Figure 2a, the cell viabilities are 
higher than 75% after 24 h, 48 h and 72 h exposure to the iron concentration of 0-50 
μg/mL. There is no decrease in cell viability when the exposure time was prolonged to 
72 h. Therefore, the Fe3O4@APS NPs have a high biocompatibility and low 
cytotoxicity.  
The MRI performance of the Fe3O4@APS NPs as contrast agents has been studied 
both in vitro and in vivo. For comparison, the Fe3O4 NPs have also been investigated. 
Figure 2b shows the T2* MRI images of the Fe3O4 NPs and Fe3O4@APS NPs 
suspensions at different Fe concentrations. The low signal intensities in the T2* MRI 
images increase with Fe concentration for both kinds of nanoparticles. Moreover, the 
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intensities are similar when the Fe concentration in the Fe3O4 NPs and Fe3O4@APS 
NPs suspensions are approximately equal. As a negative MRI contrast agent, the 
superparamagnetic Fe3O4 core can shorten the T2* values of water, resulting in a 
hyperintense signal on T2* imaging. In addition, the T2* relaxation rate (r2* = 1/T2*) 
of the Fe3O4 NPs and Fe3O4@APS NPs was calculated to be 483 mM
-1
s
-1
 (Figure 2c) 
and 400 mM
-1
s
-1
 (Figure 2d), respectively. The observed decrease in the r2* value can 
be attributed to the APS on the surface of Fe3O4 NPs, which weakens the magnetic 
properties of the NPs.  However, the Fe3O4@APS NPs remain a good contrast agent 
for MRI applications.  
The preliminary in vitro MRI signal contrast enhancement of the Fe3O4@APS NPs 
led us to evaluate its possibility to serve as a negative MRI contrast agent for MRI in 
vivo imaging. Fe3O4@APS NPs were gastrically infused into the stomach of live 
healthy male ICR mice at a dosage of 10 mg/kg. Figure 2e shows the T1 and T2 
weighted MRI images of the reference group (normal mice) and the mice after gastric 
infusion for 15 min. Comparing to the reference group, the T1 and T2 images for the 
mice after the gastric infusion show a positive and a negative contrast enhancement in 
the stomach and the bowels, respectively. Therefore, the Fe3O4@APS NPs have a 
significant signal enhancement effect as a MRI contract agent. The MRI images of the 
main organs have no specific changes even after being perfused for 4 h, 8 h and 16 h 
(Figure S5, Supporting Information), indicating the safety during Fe3O4@APS NPs 
metabolism. 
 In vivo toxicity and possible side effects of nanomedicines have to be carefully 
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studied before practical applications in clinic. In order to further demonstrate the 
safety of the Fe3O4@APS NPs, the stomachs of healthy male ICR mice were perfused 
with the Fe3O4@APS NPs at a dosage of 1.0 mg/kg/d and 2.0 mg/kg/d, respectively. 
On the 15th and 30th day, the mice were tested by MRI to examine the effect of the 
Fe3O4@APS NPs on the organs such as liver and kidney. Figure 3a and Figure S6a 
(Supporting Information) show the T2-weighted images of the livers and kidneys of 
the mouse treated by 1.0 mg/kg/d and 2.0 mg/kg/d of Fe3O4@APS NPs on the 30th 
and 15th day, together with that of the normal mouse as contrast group. Comparing 
with the contrast group, there is no obvious damage in the groups treated by 
Fe3O4@APS NPs. The T2* values shown in Figure 3b and Figure S6b (Supporting 
Information) also reveal no particular change in T2* values of the kidney and the liver 
in the range of the organ regions with different dosage and time. These results 
demonstrate that no pathological change happened in the organs of the ICR mice after 
a long time supplementation of the Fe3O4@APS NPs.  
The histopathological studies were carried out on the main organs of the ICR mice 
after the in vivo MRI testing. The histopathological images of the livers, kidneys and 
brains are presented in Figure 3c and Figure S7 (Supporting Information), which 
correspond to the ICR mice after the intragastric administration of Fe3O4@APS NPs 
for 30 and 15 days, respectively. As expected, no particles were observed in the 
organs, and no sign of organ damage or inflammation was observed, demonstrating 
the minimal side effects of the Fe3O4@APS NPs in vivo after 30 days intragastric 
administration.  
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To study the effect of the Fe3O4@APS NPs on IDA, low-iron diet Wistar rats were 
separated into different groups and fed with the designed ferralia dosage. The rats 
were weighted every week. As shown in Figure 3d, the mean body weights of all 
groups increase almost linearly with time. As expected, the model group shows the 
smallest slope of the weight growth due to serious IDA. The group treated with the 
Fe3O4 NPs has a weight growth rate higher than the model group but lower than the 
other treated and normal groups without IDA. However, the groups treated with the 
Fe3O4@APS NPs have weight growth rates comparable to that of the normal group, 
and a higher Fe3O4@APS NPs dosage results in a larger weight growth rate. 
Therefore, the Fe3O4@APS NPs treatment can improve the health of the low-iron diet 
rats.  
The Hemoglobin (HGB), Hemoglobin (RBC) and Hematocrit (HCT) are important 
parameters for the diagnosis and therapy of IDA. Therefore, the blood analyses were 
carried out for the rats studied, and the results are presented in Figure 3e-3g. Usually, 
the rats are considered as anemic when the HGB level is reduced to 75% of the 
original level. As shown in Figure 3e, the HGB values of the low-iron diet groups are 
only half of that of the normal group before ferralia treatment, which indicates a 
serious IDA of the low-iron diet rats. After the ferralia treatment, all the treated groups 
have significant increase of HGB values, while only the group supplied with the 
Fe3O4@APS NPs at a dosage of 2.0 mg/kg/d has a HGB value (136 g/L) comparable 
to the normal group (143.1 g/L). The group treated with the 1.0 mg/kg/d Fe3O4@APS 
NPs (117.1 g/L) has a curative effect similar to the group of the 2.0 mg/kg/d Fe3O4 
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NPs (117.2 g/L), demonstrating that the Fe3O4@APS NPs have more positive effect 
on HGB than the Fe3O4 NPs. The other two important parameters, RBC and HCT, 
have the trends similar to that of HGB. All blood analyses suggest that the health 
condition of the group supplied by the 2.0 mg/kg/d Fe3O4@APS NPs recovered to the 
level of the normal group. Moreover, the superoxide dismutase (SOD), glutathione 
(GSH), lactic dehydrogenase (LDH), hepcidin (HEP), malondialdehyde (MDA) and 
serum iron (SI) data were also measured after 30 days of the treatment. All results 
(Table S1, Supporting Information) demonstrate the high therapeutic effect of the 
Fe3O4@APS NPs on IDA in vivo. Considering the structure of the Fe3O4@APS NPs, 
their high therapeutic effect is attributed to both iron element supplement from Fe3O4 
and the APS stimulated hematopoietic cell generation. As a result, the Fe3O4@APS 
NPs are highly promising as an IDA drug with the additional benefit of serving as a 
MRI contrast agent. 
In conclusion, we have designed and experimentally demonstrated the Fe3O4@APS 
NPs for the targeting IDA treatment and the MRI contract agent. The stability of the 
Fe3O4@APS NPs was determined by the imitating digestion in imitated gastric acid. 
Both in vitro and in vivo toxicity studies were carried out using the cell experiments 
and intragastric administration of animal model. The blood analyses show that the 
Fe3O4@APS NPs have potent therapeutic effect on IDA, evidenced by the HGB, RBC 
and HCT values of the 2.0 mg/kg/d Fe3O4@APS NPs treated IDA rats. Moreover, 
strong MRI contrast enhancement has been observed for the Fe3O4@APS NPs. 
Therefore, the Fe3O4@APS NPs are promising candidates for IDA drugs with the 
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additional functionality as MRI contract agent.  
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Figure Captions 
Scheme 1. Schematic illustration of the design and application of Fe3O4@APS NPs 
for IDA therapy and MRI.  
 
Figure 1. a) Schematic drawing the synthesis of the Fe3O4@APS NPs. b) TEM and c) 
high-resolution TEM images of the oil soluble Fe3O4 NPs. d) TEM image of 
water soluble Fe3O4 NPs and e) their hydrodynamic profiles. f) TEM image 
of Fe3O4@APS NPs and g) their hydrodynamic profiles. h) FT-IR spectra 
and i) magnetization curves of the Fe3O4 NPs, Fe3O4@APS NPS and 
Fe3O4@APS NPs after stirring in HCl solution. Inset of i) is the image of 
the Fe3O4@APS NPs in water dispersion with (right) and without (left) 
external field. 
 
Figure 2. a) Cell viability of Hela cells after treatment with the Fe3O4@APS NPs at 
different iron concentrations after 24h, 48h and 72h. b) T2* images of the 
Fe3O4 NPs and Fe3O4@APS NPs water solution with different Fe 
concentrations. Corresponding T2* relaxation rate of the Fe3O4 NPS c) and 
the Fe3O4@APS NPs d) with respect to iron concentration. e) T1-weighted 
and T2-weighted MRI images of contrast group (normal mouse) and the 
Fe3O4@APS NPs gastric infused Male ICR mouse after 15 min.  
 
Figure 3. a) In vivo T2-weighted images of the male ICR mice liver and kidney for 
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contract group and the group treated with the Fe3O4@APS NPs at different 
Fe concentrations after 30 days. b) Signal intensity of T2* values of liver 
and kidney. c) H&E stained organ slices of the mice after 30 days 
Fe3O4@APS NPs treatment. Scale bars for all images are 100 µm. d) Body 
Weight increase with time, e) HGB concentration, f) RBC concentration and 
g) HCT values of male Wistar rats (8 per group) before and after 30 days 
treatment with the Fe3O4@APS NPs intragastric administration.    
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Scheme 1. (Wang K. et al.)                
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Figure 1. (Wang K. et al.) 
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Figure 2. (Wang K. et al.) 
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Figure 3. (Wang K. et al.)  
 
